Tens of thousands of cancer patients in England are set to benefit from a groundbreaking new injectable immunotherapy on the NHS, which can rapidly treat over a dozen types of cancer in as little as 60 seconds. This innovative treatment, known as pembrolizumab and sold under the brand name Keytruda, is designed to cut treatment time by a remarkable 90 percent, significantly reducing the burden on patients and the health service.

The new jab replaces traditional intravenous infusions, which can take up to two hours per session, with a quick subcutaneous injection into the fatty tissue of the abdomen or thigh. Depending on the specific cancer, the treatment will be administered either as a one-minute shot every three weeks or a two-minute injection every six weeks. Around 14,000 patients annually begin this therapy in England, and the majority are now expected to transition to this faster method.

Pembrolizumab is an immunotherapy that works by targeting and blocking a protein called PD-1. This protein typically acts as a 'brake' on the immune system, preventing it from attacking cancer cells. By blocking PD-1, the drug effectively 'teaches' the immune system to recognize and fight the disease. It is effective against 14 different types of cancer, including prevalent forms such as lung, breast, head and neck, and cervical cancers.

The immediate impact on patients is substantial. Shirley Xerxes, an 89-year-old patient from St Albans and one of the first to receive the jab, expressed her astonishment: "I can't believe how little time it took. I was only in the chair for a matter of minutes instead of an hour or more. It's made such a difference and gives me more time to live my life, including spending more time gardening." This sentiment highlights how the faster treatment allows patients more time outside of hospital, enhancing their quality of life.

Beyond individual patient benefits, the rapid treatment is poised to boost NHS productivity and capacity. Professor Pete Johnson, national clinical director for cancer at the NHS, emphasized the dual benefit: "This immunotherapy offers a lifeline for thousands of patients. Managing cancer treatment and regular hospital trips can be really exhausting and not only will this innovation make therapy much quicker, it will help free up vital appointments for NHS teams to continue to bring down waiting times." Health Secretary Wes Streeting echoed this, stating, "This rollout will offer quicker, more convenient care, saving patients time and helping them in their recovery with less time in hospital. Not only that - it'll also free up valuable time so clinicians can care for even more people and potentially save even more lives."

The introduction of this rapid treatment comes at a critical time for the NHS, which has faced significant challenges in cancer care. Recent analysis revealed a record 106,810 cancer patients waited over 62 days to begin urgent treatment last year, with over four in five trusts missing key targets. Cancer charities warn that such delays severely impact survival chances, potentially reducing patient survival by an average of 10 percent for every four-week delay. This innovation, therefore, is a key component of the Government's National Cancer Plan, which aims to improve survival rates and meet all existing cancer targets by March 2028.

While the benefits are significant, it's important to acknowledge that because the treatment targets the immune system, it can cause a number of serious side effects. These include breathlessness (due to a drop in red blood cells), fluid build-up, and hypothyroidism, which can lead to fatigue, weight gain, and depression. Rarer side effects can include inflammation in the heart, stomach, pancreas, and even the brain (encephalitis). However, these side effects are rare and occur regardless of whether the drug is administered intravenously or via injection.

Industry partners also lauded the development. John McNeill, Oncology Business Unit Director at MSD, the drug's manufacturer, stated, "We are pleased to introduce this new treatment option for patients that can be administered in one minute every three weeks or in two minutes every six weeks – significantly faster than IV delivery. This not only enhances the patient experience for many but also frees up valuable time for clinicians. This innovation offers a practical, patient-centred solution to improve productivity, capacity, and convenience in NHS cancer care." Michelle Mitchell, chief executive at Cancer Research UK, also welcomed the "great news," highlighting its crucial role in a time of limited NHS capacity.

In essence, this rapid cancer jab represents a pivotal advancement in oncology, promising not only a more humane and less time-consuming treatment experience for patients but also a vital tool for the NHS to enhance efficiency, reduce waiting times, and ultimately save more lives in the ongoing battle against cancer.